Atorvastatin and alkalizing treatment for autosomal dominant PKD
Treatments studied
Part of Genetic & congenital, Kidney & urinary, Women’s health & pregnancy clinical trials.
This Phase 2 study tests whether atorvastatin plus an “alkalizing” treatment (sodium bicarbonate) can slow or improve disease effects in people with autosomal dominant polycystic kidney disease (ADPKD). It specifically targets metabolic acidosis (when the body becomes “too acidic”), which may worsen kidney health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and can give informed consent
- You have ADPKD confirmed by kidney imaging and/or genetic testing, and your kidney filter rate is at least moderately reduced (estimated GFR ≥30)
- Your blood bicarbonate is low (25 or less) and you have metabolic acidosis
- If you can become pregnant, you are not pregnant and you will use reliable birth control during the study and for 30+ days after stopping
- You must not be allergic to atorvastatin or sodium bicarbonate
- You must not have certain serious conditions (like significant liver or muscle problems) and must avoid specific prohibited medications during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a medicine called an SGLT2 inhibitor (a type of diabetes drug) can help control calcium and magnesium levels in people with a genetic kidney disease called ADPKD. The goal is to see if it improves kidney health over a short period.
This Phase 3 study tests whether taking metformin can slow the decline of kidney function in adults with autosomal dominant polycystic kidney disease (ADPKD). You may be eligible if you have ADPKD and signs that your kidneys are starting to decline faster than expected.
This trial tests a new drug, ABBV-CLS-628, for people with autosomal dominant polycystic kidney disease (ADPKD). The goal is to see if it slows kidney function decline and is safe to use.
This trial tests a new study drug called AZD1613 for adults with a certain type of kidney disease (ADPKD). Researchers want to see if it is safe, how the body handles it, and what the right dose might be.
This trial studies whether taking sodium bicarbonate changes “energy” in cells and improves metabolic acidosis (an acid build-up) in people with moderate-to-severe chronic kidney disease. You may be able to join if your kidney function and blood bicarbonate levels fit their targets and you meet safety rules.
This trial tests if the cholesterol-lowering drug bempedoic acid can slow kidney function loss in people with autosomal dominant polycystic kidney disease (ADPKD). It may offer a new option to protect your kidneys.
Hear when a new Autosomal Dominant Polycystic Kidney Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.